Clear Labs Granted EUA by FDA for SARS-CoV-2 Novel Descriptive Diagnostic
NGS-enabled platform tracks infection clusters for contact tracing and monitors emerging mutations, combining once separate aspects of screening and genomic surveillance SAN CARLOS, CALIF. (PRWEB) SEPTEMBER 24, 2020 Clear Labs, providers of the only fully automated and intelligent next-generation sequencing (NGS) in vitro diagnostic (IVD) platform, today announced that the U.S. Food and Drug Administration (FDA) has... Read more